Download Files:
Tuxobertinib
SKU
HY-136789-10 mg
Category Reference compound
Tags Cancer, EGFR, JAK/STAT Signaling;Protein Tyrosine Kinase/RTK
$70 – $750
Products Details
Product Description
– Tuxobertinib (BDTX-189) is a potent, orally active and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations, including EGFR/HER2 exon 20 insertion mutants. Tuxobertinib shows KDs of 0.2, 0.76, 13 and 1.2 nM for EGFR, HER2, BLK and RIPK2, reapectively. Anticancer activity[1].
Web ID
– HY-136789
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C29H29ClN6O4
References
– [1]Elizabeth Buck, et al. BDTX-189, a Potent and Selective Inhibitor of Allosteric EGFR and HER2 Oncogenic Mutations.
CAS Number
– 2414572-47-5
Molecular Weight
– 561.03
Compound Purity
– 99.94
SMILES
– C=CC(NC1=CC2=C(NC3=CC=C(OCC4=NC=CC=C4)C(Cl)=C3)N=CN=C2C=C1OCCN5CCOCC5)=O
Clinical Information
– Phase 2
Research Area
– Cancer
Solubility
– DMSO : 41.67 mg/mL (ultrasonic)
Target
– EGFR
Isoform
– EGFR/ErbB1/HER1;ErbB2/HER2
Pathway
– JAK/STAT Signaling;Protein Tyrosine Kinase/RTK
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.